Kathryn Kolibaba, MD of US Oncology Research discusses the MAGNIFY study and its impact on high-risk indolent NHL patients at the 2017 Annual Meeting Annual Meeting in Chicago, IL.
Results of the MAGNIFY study for high-risk indolent non-hodgkin lymphoma patients
